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Medium throughput breathing 
human primary cell alveolus-on-
chip model
Janick D. Stucki1,8, Nina Hobi1,2,8, Artur Galimov1, Andreas O. Stucki1, Nicole Schneider-
Daum3, Claus-Michael Lehr3, Hanno Huwer4, Manfred Frick  2, Manuela Funke-Chambour5,6, 
Thomas Geiser5,6,8 & Olivier T. Guenat  1,5,7,8
Organs-on-chips have the potential to improve drug development efficiency and decrease the need 
for animal testing. For the successful integration of these devices in research and industry, they must 
reproduce in vivo contexts as closely as possible and be easy to use. Here, we describe a ‘breathing’ 
lung-on-chip array equipped with a passive medium exchange mechanism that provide an in vivo-
like environment to primary human lung alveolar cells (hAEpCs) and primary lung endothelial cells. 
This configuration allows the preservation of the phenotype and the function of hAEpCs for several 
days, the conservation of the epithelial barrier functionality, while enabling simple sampling of the 
supernatant from the basal chamber. In addition, the chip design increases experimental throughput 
and enables trans-epithelial electrical resistance measurements using standard equipment. Biological 
validation revealed that human primary alveolar type I (ATI) and type II-like (ATII) epithelial cells could 
be successfully cultured on the chip over multiple days. Moreover, the effect of the physiological cyclic 
strain showed that the epithelial barrier permeability was significantly affected. Long-term co-culture 
of primary human lung epithelial and endothelial cells demonstrated the potential of the lung-on-chip 
array for reproducible cell culture under physiological conditions. Thus, this breathing lung-on-chip 
array, in combination with patients’ primary ATI, ATII, and lung endothelial cells, has the potential to 
become a valuable tool for lung research, drug discovery and precision medicine.
Organs-on-chips are advanced in vitro models mimicking the cellular microenvironment found in vivo1. These 
models are widely seen as promising tools for preclinical validation and have the potential to improve and accel-
erate drug development2–4. However, to make organs-on-chip widely available, key challenges must be overcome. 
First, these systems must mimic the cellular microenvironment. In addition, it is necessary to consider handling 
issues, such as ease of access to the cells, the potential of long-term culture and analysis of cells, and simplicity 
of handling5. In particular, long-term experiments are crucial for observation of cell–cell interactions that occur 
over extended time periods (e.g., cellular differentiation or pathological conditions such as fibrosis)4. Such exper-
imental designs require regular medium exchange to provide sufficient nutrients and remove metabolic waste 
products. Previous organ-on-chip studies report medium exchange by active or passive pumping systems, either 
external or directly integrated on-chip6–11. Active pumping is often cumbersome, due to the requirement for 
tubing and external equipment, but passive pumping offers simple and elegant solutions. Passive systems can be 
based on surface tension12, hydrostatic13–15, capillary forces16 or evaporation effects17,18. Moreover, because they 
do not contain any moving parts, they are simple to produce and mechanically robust.
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Due to their complex architecture located in a dynamic environment, the lung alveoli are difficult to mimic 
in-vitro. In vivo, the air–blood interface is an ultrathin barrier of only a few micrometers19, consisting of tight, 
semi-selective epithelial- and endothelial cell layers enveloped by the extracellular matrix (ECM)20,21, rhythmi-
cally expanding and contracting. Numerous 2D and 3D in-vitro models of the lung alveolar barrier have been 
reported22,23, but only few reproduced the mechanical forces created by the respiratory movements. In 2007, 
Takayama and colleagues mimicked those forces using liquid plugs transported by airflow to assess cellular dam-
age24. In a further study, they investigated the effects of physiological and pathophysiological levels of both fluid 
and solid mechanical stresses on alveolar epithelial cells25. Using a similar technique, Higuita et al. investigated 
how airway wall stiffness influences epithelial cell injury26. More recently, Schürch et al. used a captive bubble 
surfactometer system27, to expose the surfactant film lining the epithelium to cyclic compression and expansion28. 
In addition to the cyclic stretch, Campillo et al. developed an in-vitro system equally capable of inducing high 
frequency intermittent hypoxia, a hallmark of obstructive sleep apnea29.
In sharp contrast to the in-vitro models mentioned above, Huh et al. reported in 2010 for the first time about 
a microfluidic system with an integrated lung alveolar barrier that was cyclically stretched in one direction 
to mimic the respiratory movements. The device, called lung-on-chip, was equipped with a thin, porous and 
elastic membrane, on which alveolar epithelial cells and endothelial cells were cultured on the apical and basal 
side, respectively6. More recently our group reported about a new lung-on-chip device with an alveolar barrier 
stretched in three dimensions, similar to the in vivo situation. The breathing movements were induced by the 
cyclic deflection of a microdiaphragm, similar to the movements of the in-vivo diaphragm. Primary human lung 
alveolar epithelial cells from patients were cultured under physiological mechanical strain for the first time on 
such a device30. Lately, Jain et al. described an alveolus-on-a-chip model using primary human lung alveolar 
epithelial and lung endothelial cells to mimic pulmonary thrombosis. In the later case, the cells were however not 
exposed to cyclic strain31.
Here, we present a new lung-on-chip device equipped with a pumping system that combines both active and 
passive pumping, enabling passive medium flow at freely chosen time points. In contrast to our earlier work, the 
new lung-on-chip is equipped with passive medium exchange that enables not only the reproduction of the cyclic 
mechanical stress, but also long-term cell culture at the air–liquid interface, and thus reproduces the unique 
aspects of the lung microenvironment even more closely. The details of the microenvironment have significant 
impacts on a wide range of biological processes, including epithelial cell polarity and cell differentiation, which 
in turn play important roles in determining physiological functions32–38. Furthermore, we describe a breathing 
lung alveolar barrier consisting of primary human alveolar epithelial and lung endothelial cells cultured in an 
in vivo–like environment. The presence of type I- (ATI) and type II-like (ATII) alveolar epithelial phenotypes 
is demonstrated for the first time in a lung-on-chip. Using this system, we assessed the effect of physiological 
stretching on cell morphology and barrier permeability of primary ATI- and ATII-like cells. Importantly, this new 
system is compatible with a number of standard readout techniques, including ELISA, trans-epithelial electrical 
resistance (TEER), permeability assays, qPCR, immunostaining and electron microscopy. This device opens up 
new possibilities for basic research of the alveoli and preclinical testing of drug candidates, and will ultimately 
enable testing of cells from individual patients in precision medicine approaches.
Materials and Methods
Lung-on-chip design and fabrication. A detailed description of the design and of the operation of the 
lung-on-chip is given in the supplementary section (see supplementary information “Lung-on-Chip design and 
operation”). Briefly, the lung-on-chip consists of reversibly bonded fluidic and pneumatic parts with six inde-
pendent lung alveolar barriers (Fig. S1). The fluidic part comprises two structured plates – the top and middle 
plates – between which a thin, porous, elastic PDMS membrane is sandwiched. The top plate is made of either 
PDMS or polycarbonate (PC), whereas the middle plate is made of PDMS. The pneumatic part comprises a struc-
tured PDMS base plate, on which a 40-µm thick PDMS membrane is attached by plasma O2 (Harrick plasma). 
The top and PDMS middle plate of the fluidic part, and the base plate of the pneumatic part were produced by 
soft lithography39. Briefly, 10:1 PDMS (Sylgard 184, Dow Corning) was mixed, degassed and casted in hard plastic 
molds (Weidling C, Weicon) obtained from structured aluminum molds (ki-Mech GmbH). The PDMS was cured 
in an oven at 60 °C for at least 24 h. The 3 mm in diameter elastic membrane with pores of 3-µm (density of the 
pores: 800’000 pores/cm2) was fabricated as described previously30. In brief, 10:1 PDMS pre-polymer was spread 
between a silicon mold and a PET sheet (DuPont Teijin Films, Melinex® 411) using a roller. The mold and PET 
sheet were then clamped between two glass slides and cured at 60 °C for at least 24 h. Afterwards, the membrane 
was released and bonded to the middle plate with O2 plasma (Harrick Plasma). The PC top plate, fabricated by 
standard machining, was first coated with 25 μL of Wacker PRIMER G790 (Ameba AG) and placed on a hot plate 
(80 °C for 20 min). Then, the PC top was placed on an uncured 40-µm layer of PDMS– spin coated on a glass plate 
(1700 rpm for 60 s) – cured overnight in the oven at 60 °C and removed from the glass plate. The middle part 
with the bonded thin and porous membrane was then assembled with the PDMS coated top part. To assemble 
the lung-on-chip array, the pneumatic and fluidic parts were visually aligned, brought in contact, and reversibly 
attached by manual pressing using adhesion forces alone.
Lung-on-chip validation. Initial chip filling. The lung-on-chip was assembled, and the inlet well was filled 
with cell culture medium. To fill the chip with medium, the valves were opened, and negative pressure was applied 
at the outlet well using a 1 mL syringe. Filling was recorded with a color camera (iDS UI-3370CP-C-HQ, iDS).
Medium exchange. The lung-on-chip was assembled, filled with cell culture medium, and placed in an incu-
bator for at least 2 h. The inlet and outlet wells were emptied, the inlet well was filled with fluorescein sodium 
(Sigma-Aldrich) in PBS (1 mg mL−1), and the valves were opened to initiate the medium exchange. Medium 
www.nature.com/scientificreports/
3SCIENTIfIC RepoRTS |  (2018) 8:14359  | DOI:10.1038/s41598-018-32523-x
exchange was monitored in fluorescence mode with an upright microscope (Axioplan 2, Zeiss) equipped with 
a color camera (iDS UI-3370CP-C-HQ, iDS). The resultant movie was processed using the open-source image 
analysis software Fiji (http://fiji.sc/Fiji). After cropping to the correct starting time, corresponding to the time 
point when the valves opened, a kymograph (pixel intensity along a defined line over time) was created of the 
beginning of the outlet channel of the basal cell culture chamber. The kymograph was used to determine the time 
at which the intensity signal no longer changed, which corresponds to complete filling of the basal chamber (i.e., 
the end of the exchange).
Thin membrane deflection. As described above, the chip was assembled, filled with cell culture medium, and 
placed in the incubator overnight. Membrane deflection was monitored with an Axioplan 2 upright microscope 
equipped with a high-speed camera (Basler piA640-210gc GigE, Basler AG). The inlet and outlet wells were emp-
tied completely, and then the inlet well was filled with cell culture medium. During the exchange, a small light 
spot was projected onto the membrane that changed its shape according to the deflection. The movement of the 
membrane (i.e., the shape change of the light spot) was recorded at 200 fps. The movie was then processed using 
Fiji. Brightness and contrast were adjusted, and kymograph was created for a line through the center of the light 
spot. Afterwards, the edges were detected, and the data (x- and y-positions) of the edges were saved. The data were 
then further analyzed in Matlab (MathWorks) to extract the corresponding deflection. For more information, see 
Fig. S2.
Applied strain. The lung-on-chip was assembled and filled with cell culture medium. The mechanical strain 
generated in the device was quantified by taking images in the center of the membrane in the non-deflected and 
deflected states. These images were processed in Fiji and Matlab to calculate the inter-pore distance, which was 
then used to compute the linear strain (Fig. S3).
Standard cell culture protocols. Bronchial epithelial 16HBE14o- cells (obtained from the late Dr. Dieter 
Gruenert, University of California–San Francisco) were cultured in MEM medium (Gibco) supplemented 
with 10% FBS (Gibco), 1% L-Glutamine (2 mM, Gibco), 1% penicillin, and 1% streptomycin (P/S, Gibco). RFP 
labeled primary human lung microvascular endothelial cells (VeraVec, Angiocrine Bioscience) were cultured 
in EGM™−2 medium (Lonza) supplemented with 5% FBS (Sigma), 1% penicillin (Gibco), 1% streptomycin 
(Gibco), and VEGF growth factors according to the manufacturers protocol for the EGM™-2MV BulletKit. 
Primary human alveolar epithelial cells (hAEpCs) were isolated according to an established protocol described 
by Daum et al.40. Briefly, alveolar epithelial type II (AT II) cells were isolated from tissue obtained from healthy 
areas removed from patients undergoing lung tumor resection surgery. All patients gave informed written con-
sent for usage of surgical material for research purposes, which was approved by ethical committee from the 
Ärztekammer des Saarlandes. All procedures were carried out in accordance with institutional guidelines from 
Saarland (Germany) and from the Canton of Bern (Switzerland). The ATII cell population was purified by a 
combination of cell attachment procedure, density gradient centrifugation via Percoll®, and positive magnetic 
cell sorting as in detailed described in Daum et al.40. Directly after isolation, hAEpCs were resuspended in 40 mL 
Small Airway Growth Medium (SAGM™, Lonza) with BulletKit (CC-3118, Lonza), supplemented with 1% FBS 
(Sigma) and 1% P/S. All cell types were maintained in a standard cell culture environment (37 °C, 5% CO2 in air). 
To verify the integrity and barrier function of shipped hAEpCs, primary cells were seeded on 0.33 cm2 Transwell® 
filters (Corning, C#3470), and TEER was measured daily with a chopstick electrode connected to an EVOM2 
epithelial volt/ohm meter (World Precision Instruments) as previously described40 (data not shown).
Coating and cell seeding on chip. When using the 16HBE14o- cell line, the porous PDMS membrane was 
coated with collagen IV (2.5 µg cm−2, Sigma-Aldrich) overnight in the incubator. The cells were seeded at a den-
sity of 1.5 × 105 cells cm−2 in a 15 µL droplet on the apical side of the membrane. After adhesion (2 h), the apical 
cell culture well was filled to 80 µL. When working with primary cells, the porous PDMS membrane was coated 
with a bovine collagen I (Sigma-Aldrich) and human fibronectin (Corning) solution, for 4 hours in the incuba-
tor, as previously described for inserts by Daum et al.40. The coating solution was removed, and the membrane 
rinsed with 80 µL of sterile water. The chips were then placed under UV for 45 min to allow drying. For hAEpC 
mono-culture, the chips were first closed and filled with cell culture medium. Then, the hAEpCs were seeded 
(3 × 105 cells cm−2) on the apical side of the membrane in a 15 µL droplet. After 4 h, the cell culture well was filled 
to 80 µL with cell culture medium. In co-culture experiments, VeraVec cells (3 × 104 cells cm−2) were first seeded – 
using a standard pipette – on the basal side of the membrane in a 15 µL droplet. For this procedure, the fluidic 
part of the chip was flipped so that the basal side of the porous membrane faces upwards. After 4 h, once the 
endothelial cells adhered on the membrane, 5 µL were removed from the drop, and the fluidic part flipped back. 
The fluidic part was then assembled to the pneumatic part, to close the chip, which was then filled with medium, 
see Fig. S2. Afterwards, the hAEpCs (3 × 105 cells cm−2) were seeded on the apical side in a 15 µL droplet. After 
4 h, the cell culture well was filled to 80 µL with cell culture medium.
Cell viability assay. 16HBE14o- cells were grown in MEM with 10% FBS until they reached confluence (3 
days, daily medium exchange). The apical supernatant was collected, and the chip was closed and filled with MEM 
with 1% FBS (MEMs). Cell viability was measured using the PrestoBlue® assay (Life Technologies). In brief, 
after 1 h incubation with PrestoBlue® (1:10 in MEMs), 50 μL of apical solution was collected and transferred to a 
96-well plate. The readout was carried out on a multi-well plate reader (M1000 Infinite, Tecan) at 570 nm excita-
tion and 585 nm emission. The apical chamber was washed with PBS with calcium, and the medium in the apical 
and basal cell culture chamber was replaced with MEMs. The chips were then transferred to an incubator and 
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connected to the external electro-pneumatic setup. They were either stretched (dynamic) or maintained under 
static conditions. Viability was measured daily in the supernatant from the apical side.
Long-term alveolar epithelial and endothelial co-culture. As described above, the VeraVec (P. 2) cells 
were seeded on the basal side. After cell attachment, the chip was closed and filled with EGM™-MV2. VeraVec 
cells were grown on the chip for 2 days (with no medium on the apical side) in EGM™-2MV. Then, the EGM™-
2MV medium was exchanged with a 1:1 mixture of EGM™-2MV and SAGM™. After medium exchange, the 
hAEpCs were seeded on the apical side, as described above (day 0). Cell culture medium was exchanged every 
second day. TEER measurements started at day 1. TEER was measured daily using a commercially available 
96-well plate electrode (STX100M; World Precision Instruments) and an EVOM2. The TEER was measured in 
submerged cell culture conditions for up to 22 days. The specific design of the lung-on-chip enables to hold the 
electrodes tightly between the outlet well and the culture well. This allows an accurate and reproducible posi-
tioning of the TEER electrodes. To measure TEER, electrodes were placed into the cell culture well and outlet 
well, and then the valves were opened. TEER background was measured on a porous membrane chip containing 
no cells. Background-subtracted TEER values (Ω) were multiplied by the surface area (0.07 cm2) to calculate 
Ω × cm2.
Stretching protocol. The lung-on-chip was designed to create a three-dimensional physiological surface 
strain of 16.6%. In view to make cross-comparison41,42 possible with other systems using a uniaxial strain, the 
surface strain is indicated in the following as linear strain of 8%. The membrane was cyclically stretched at 0.2 Hz 
using an external electro-pneumatic setup. The pressure curve was modeled as a triangle wave.
qRT-PCR protocol. Total RNA was isolated and purified from genomic DNA using the NucleoSpin® RNA 
XS kit (Macherey Nagel). To harvest cells from the lung-on-chip, an aliquot of 100 μL lysis buffer was applied to 
every well, pipetted up and down three times, and transferred to a separate tube. RNA concentration and purity 
was analyzed on a NanoDrop Lite (Thermo Scientific). Purified total RNA was used for cDNA preparation with 
the Super Script III Reverse Transcriptase kit (Life Technologies) employing random hexamer primers. cDNAs 
were amplified by quantitative real-time PCR using SYBR® Select Master Mix (Thermo Scientific) on a 7500 Fast 
Start Real-Time PCR system (Applied Biosystems). Primers for ENACα (Cat.no: QT0002883) and Caveolin1 
(Cat.no: QT00012607) were purchased from Qiagen. The primer sequences for 18S and hSP-C are provided in 
Table S1.
Permeability assay. hAEpCs were seeded on a chip as described above and cultured on the apical side for 2 
days under static and submerged conditions. They were then placed at the air–liquid interface and cultured under 
static or dynamic conditions for 3 additional days. On day 5, the apical side was washed with PBS with calcium, 
which was subsequently exchanged with 80 μL of a permeability solution [1 µg mL−1 FITC-sodium (0.4 kDa, 
Sigma-Aldrich) and 1.5 mg mL−1 RITC-dextran (70 kDa, Sigma-Aldrich) in SAGM™ medium]. The chip was 
then transferred to the incubator and incubated in static conditions. After 2 h, the apical permeability solution 
was removed, the apical side was washed once with PBS with calcium, following which the PBS was removed, 
and the medium in the basal chamber exchanged. The supernatant solution was collected from the outlet well. A 
50-µL aliquot of this solution was transferred to a 96-well flat-bottom plate and analyzed with a microplate reader 
(M1000 Infinite, Tecan) at 460 nm excitation/515 nm emission for FITC-sodium and 553 nm excitation/627 nm 
for RITC-dextran. The apparent permeability coefficient (Papp) was calculated according to equation (1), dQ/dt 
being the transport rate and C0, the initial concentration of the permeability solution tested and A the surface area 












Immunofluorescence staining and imaging. For immunofluorescence imaging, cells were washed twice 
with PBS with calcium and fixed for 12 min at room temperature (RT) with 4% paraformaldehyde in PBS without 
calcium. The fluidic and pneumatic parts were disassembled to allow efficient rinsing. After three washes with 
PBS without calcium, the cells were permeabilized and blocked for 30 min at RT with 0.1% Triton X-100 in 2% 
BSA/PBS solution. After an additional wash with PBS without calcium, the samples were ready for staining. All 
secondary antibodies were purchased from Thermo Fisher Scientific. Mono-culture staining: primary mouse 
anti-Zo-1 antibody (C# 33-9100, Fisher T Scientific), primary rabbit anti-mature SP-C antibody (C# WRAB-
76694, Sevenhills), primary mouse anti-ABCa3 (C# ab24751, Abcam) and primary goat anti-caveolin-1 antibody 
(C# ab36152, Abcam) were diluted 1:100 in 0.2% BSA and incubated for 1.5 h at RT. After four washes times 
with PBS, secondary antibody donkey anti-mouse Alexa Fluor 674, donkey anti-rabbit Alexa Fluor 488 (both 
diluted 1:500) and 1 mg mL−1 Hoechst 3342 (diluted 1:1000) in 0.2% BSA/PBS were added, and the sample was 
incubated for 1 h at RT in the dark. Co-culture staining: Primary anti-E-cadherin goat antibody (C#N-20, Santa 
Cruz Biotechnology) and Zo-1 diluted 1:100 in 0.2% BSA/PBS were added, and the sample was and incubated for 
1.5 h at RT. After four washes times with PBS on both sides, secondary anti-mouse Alexa Fluor 647 and anti-goat 
Alexa Fluor 488 (1:500) and 1 mg mL−1 Hoechst 33342 (1:1000) in 2% BSA/PBS were added, and the sample was 
incubated for 1.5 h at RT in the dark.
Images were obtained using either a confocal laser scanning microscope (Zeiss LSM 710) or an inverse micro-
scope equipped with a spinning disc (Nikon Ti-E, X-light V2, CrestOptics), using appropriate filter settings. 
Acquired images were further processed in Fiji to optimize visualization (background subtraction, contrast 
enhancement, change of color channels, etc.).
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Electron microscopy. After removal of culture media, cells on the membrane were submerged in a fixative, 
prepared as following: 2.5% glutaraldehyde (Agar Scientific) in 0.15 M HEPES (Fluka) with an osmolarity of 
670 mOsm, adjusted to pH 7.35. Samples remained in the fixative at 4 °C for at least 24 h before further processing. 
They were then washed three times for 5 min each with 0.15 M HEPES, and postfixed with 1% OsO4 (EMS) in 
0.1 M Na-cacodylate-buffer (Merck) at 4 °C for 1 h. Thereafter, the cells were washed three times for 5 min each 
in 0.1 M Na-cacodylate-buffer and dehydrated in 70%, 80%, and 96% ethanol (Alcosuisse) for 15 min each at RT. 
Subsequently, cells were immersed in 100% ethanol (Merck) three times for 10 min each, and then submerged 
in acetone-Epon (1:1) overnight at RT. The next day, the cells were embedded in Epon (Fluka) and left to harden 
at 60 °C for 5 days. Sections were generated on an ultramicrotome UC6 (Leica Microsystems, Vienna, Austria): 
first semi-thin sections (1 μm) for light microscopy, which were stained with 0.5% toluidine blue O (Merck), and 
then ultrathin sections (70–80 nm) for electron microscopy. The sections were mounted on single-slot copper 
grids and stained with uranyl acetate and lead citrate using an ultrastainer (Leica Microsystems). Sections were 
analyzed with a transmission electron microscope (CM12, Philips) equipped with a digital camera (Morada, Soft 
Imaging System) and image analysis software (iTEM).
Statistics. All data are presented as means ± standard deviation (SD). Two-tailed unpaired Student’s t-test 
was used to assess significance of differences. Statistical significance was defined as follows: *P < 0.05, **P < 0.01, 
***P < 0.001. The number of repeats performed for each experiment varied between three and eleven. The exact 
number is indicated in the corresponding figure legend.
Results and Discussion
Lung-on-chip with a passive exchange mechanism. A 3.5-μm porous PDMS membrane was inte-
grated in this lung-on-chip device. To our knowledge, this is the thinnest porous PDMS membrane used in an 
organ-on-chip device to date6,8,30,31,43. The thickness of 3.5-μm was chosen as the best compromise between struc-
tural integrity and thickness, and can be fabricated reliably and reproducibly. PDMS was used due to its excellent 
elastic properties44 and biocompatibility45,46. The membrane covers a circular area with a diameter of 3 mm. The 
low area decreases the number of primary cells necessary to establish a confluent barrier, while at the same time 
providing sufficient material for downstream processes such as PCR. Due to its thinness and relatively large 
surface area, the membrane is highly sensitive to pressure gradients. Therefore, the biggest challenge of the new 
lung-on-chip design was to integrate a perfusion concept that is simple in application, but does not irregularly 
deflect the thin porous membrane during medium exchange.
To monitor the deflection of the thin membrane during medium exchange, the forces acting on the membrane 
need to be precisely controlled. Although this could be done with syringe or peristaltic pumps6,47, or the use of, 
e.g., tilting tables14,48, this would increase the overall handling complexity and error rate. From the standpoint 
of simplicity, we decided to integrate a passive exchange mechanism based on hydrostatic and surface tension 
forces. During medium exchange, these two forces counteract each other on the membrane, allowing us to control 
membrane deflection by defining the flow resistance of the microchannels before and after the membrane. These 
critical flow resistance values could be appropriately defined using a mathematical model of medium exchange 
inside the chip (see SI: Mathematical modeling). The final design of the lung-on-chip array includes six wells, 
each of them representing an independent alveolar barrier system (Fig. 1). This design allows two to six times 
more experiments to be performed than on previously developed breathing lung-on-chip devices6,30. The chip 
is composed of a fluidic and pneumatic part, which can be assembled reversibly (Fig. S1). This two-part setup 
facilitates cell seeding on either side of the membrane, as described previously30.
Figure 1 shows a schematic cross-section of one alveolar barrier system including all features described above. 
A detailed description of the dimensions and mode of operations is given in the Supplementary Information. 
The fluidic part includes an inlet and outlet well, the porous membrane, a microchannel that connects the inlet 
and the outlet, an apical cell culture well, and a basal cell culture chamber; the well and chamber hold a volume 
of 80 μL each. The pneumatic part is composed of two valves and a micro-diaphragm. The chip has two differ-
ent operation modes: (i) breathing and (ii) medium exchange. During breathing, the valves are closed, and the 
micro-diaphragm is cyclically deflected via an external electro-pneumatic setup. Because fluid is incompressible 
and the basal chamber is closed, the movements of the micro-diaphragm are directly transferred to the thin mem-
brane. In this way, it is possible to recreate the three-dimensional breathing motions. In medium exchange mode, 
breathing is stopped, and the inlet well filled with fresh medium. The valves are then opened by applying negative 
pressure via the external electro-pneumatic setup. The medium in the basal chamber is exchanged passively by 
means of hydrostatic and surface tension forces alone. After the medium is exchanged, the valves are closed again. 
The used medium (basal supernatant) can be collected from the outlet well and used for further analysis. In the 
final step, the inlet and outlet wells are emptied, and breathing mode is restarted.
This new lung-on-chip device, with a passive exchange mechanism, is simple to handle and enables long-term 
breathing of co-cultures at air–liquid interface, up to 22 days. Furthermore, because no external tubing or pumps 
are used for the perfusion, the risks of contamination, leakage, and air bubbles are nearly eliminated46,49,50. 
Additionally, the semi-open design makes it easy to create and maintain air–liquid cell culture conditions, which 
is usually difficult inside small microfluidic channels in combination with elastic membranes due to high surface 
tension forces51. Furthermore, it ensures similar gas supply as for conventional cell-culture dishes placed in the 
incubator.
Lung-on-chip design validation. After mathematical modeling, chip design and fabrication, the 
lung-on-chip was experimentally tested for its functionality. In the first step, the chip had to be assembled and ini-
tially filled. To close the chip, the pneumatic part was aligned with the fluidic part and reversibly closed by manual 
pressure. The reversible closing of the chip allows separation of the different parts at the end of the experiment, 
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enabling high-resolution imaging. A working lung-on-chip requires successful chip sealing and initial filling. 
Fortunately, both can be tested in one step, because if the chip were not sealed after closing, it would not be pos-
sible to fill it. To evaluate this issue, the chip was reversibly closed, and basal chamber filling was recorded under 
the microscope. The specific 3D design of the basal chamber, as well as the initial hydrophobicity of the PDMS, 
enabled filling of the chip without incorporation any air bubbles (Fig. S2). Successful filling proved that the chip 
was well sealed. One might also consider testing the delamination pressure of the chip; however, because we were 
creating negative pressure inside the basal cell culture chamber, delamination could not occur during normal 
chip operation. The lung-on-chip was designed to generate about 8% linear strain, well within the physiologically 
relevant range of 5–12% strain in vivo52,53. The measured linear strain inside the lung-on-chip was 7.6 ± 0.66% on 
average (see Fig. S3).
In the next step, medium exchange was tested and quantified. The medium in the apical well can be simply 
exchanged using standard pipettes. In the basal chamber, the medium is exchanged via the passive mechanism. 
Figure 2A depicts replacement of the cell culture medium in the basal chamber with fluorescein solution. The 
image sequence shows that the medium was exchanged efficiently without introducing any air bubbles.
We then tested the lung-on-chip to determine whether it works as mathematically modeled. To this end, 
we analyzed the dependency between hydrostatic pressure and the time needed to exchange the medium was 
analyzed. To vary the hydrostatic pressure, different volumes of cell culture medium were pipetted into the inlet 
well. Then, the valves were opened, and the exchange times were measured; these experimental times were then 
compared to the predictions of the mathematical model. The results of this comparison are shown in Fig. 2B. The 
experimental times corresponded very well with the predictions, indicating that the chip worked as proposed.
To further confirm this, we quantified the movement of the thin membrane during medium exchange. To 
measure the fast deflection of the thin porous membrane during the exchange, we developed an optical measure-
ment technique (Fig. S4). Using this technique, the deflection as a function of time could be measured experi-
mentally. Figure 2C shows a comparison between the predicted membrane deflection and the experimental data. 
The results show that the mathematical model slightly over-estimates the membrane deflection, possibly due 
to differences in the Young’s modulus of PDMS or small variations in the dimensions of the membranes tested. 
Nevertheless, the experimental deflection pattern corresponded well to the prediction of the model. Thus, these 
results provide further confirmation that the lung-on-chip is working as intended. The maximal deflection of the 
thin, porous membrane during exchange was −112 μm, corresponds to less than 0.4% linear strain. This small 
strain can be considered negligible if the cells are stretched to simulate breathing motions, during which the cells 
are exposed to ~8% linear strain. By contrast, if the chips are kept under static conditions, this weak strain might 
lead to a short-term cell response. However, because the cells are cultured over multiple days, and the medium is 
exchanged only daily or every second day, this effect could easily diminish over time. In addition, once endothe-
lial and/or epithelial cells are cultured on the membrane, the deflection will be even smaller due to the increase 
Figure 1. Concept of the newly developed lung-on-chip. Top: in-vivo, the lung expands following the 
contraction of the diaphragm. The breathing motions are transferred from the organ-level to the individual 
alveoli. The alveolar barrier consists of a tight alveolar epithelial cell layer – made of type I (AT I) and of type 
II (AT II) alveolar epithelial cells – and of endothelial cells (EC) between which the basal membrane (BM) is 
sandwiched. Bottom: Schematic cross-sections of the lung-on-chip with two operation modes: (i) Breathing 
and (ii) Medium exchange modes. The breathing motions of the alveolar barrier are induced by a bio-inspired 
microdiaphragm. When a cyclic vacuum is applied in the microcavity, the microdiaphragm is deflected. Two 
valves located on each side of the basal compartment can be opened to exchange the cell culture medium. 
Hydrostatic and surface tension forces transport the flow. After the exchange the valves are closed and the 
supernatant can be sampled from the outlet. Right: Photograph of the lung-on-chip with 6 independent alveolar 
barrier systems filed with cell culture medium.
www.nature.com/scientificreports/
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in overall stiffness. Therefore, we can neglect the possible effect of strain resulting from medium exchange on the 
cellular response. The mathematical model was also used to calculate the shear stress acting on the cells during 
exchange (Fig. S5), which was determined to be only 5 × 10−1 dyne cm−2. This is one order of magnitude smaller 
than the shear stress observed in human microvessels (3–10 dyne cm−2)54, and is thus unlikely to affect the cells.
Validation of cell culture on chip. In an initial step, we tested the utility of the new device and compared 
daily chip handling routines, such as cell seeding, medium exchange, and stretching. 16HBE14o- cells were cul-
tured on the chip for a total of 6 days. Medium was exchanged every day as outlined above. After 3 days, the chip 
was closed, and the cells were cultured under either static or dynamic conditions. We analyzed cell viability using 
the PrestoBlue® assay. For the readout, the apical supernatant was transferred to a separate 96-well plate. As 
shown in Fig. 3, 24 h of cyclic physiological stretching was sufficient to induce a significant increase in cell viabil-
ity in comparison to static conditions. Viability continued to improve until the experiment was stopped on day 6. 
As expected, the integrated passive medium exchange mechanism simplified the establishment and maintenance 
of long-term cell cultures, and the results were comparable with previously reported data55. The readout could 
also be performed by placing the chip directly into the TECAN reader (Fig. S6).
Primary human alveolar epithelial cells on chip. A major challenge for microfluidic devices is the cul-
tivation of primary cells46,56, which are often very stress-sensitive and unable to proliferate in vitro. Consequently, 
to generate a confluent monolayer, seeding densities and coatings must be optimized. For establishment of an 
advanced alveolus-on-chip, it is necessary to use primary alveolar epithelial cells (ATI and ATII cells), which play 
distinct roles in the alveolar microenvironment. ATI cells are large, flat, intricately branched cells with multiple 
cytoplasmic leaflets, and are almost devoid of organelles. Their main function is to provide an extensive, thin 
alveolar barrier that enables optimized (gas) transport21,57. On the other hand, the main functions of ATII cells 
are the synthesis, storage, and release of pulmonary surfactant into the alveolar hypophase, where it improves 
lung compliance and prevents alveolar collapse58. ATII cells also regulate the alveolar compartment and respond 
to alveolar injury by proliferating, serving as progenitors for both type I and type II cells59. The two cell types play 
different roles in alveolar fluid and ion transport60–62, reflected by their distinct expression patterns of various 
aquaporins and tight junctions proteins63,64.
Figure 2. Characterization of the lung-on-chip array. (A) Time sequences of the medium exchange, visualised 
with a fluorescence dye (FITC-Sodium in PBS). Scale bar: 2 mm. (B) Comparison of the experimental 
and theoretical medium-exchange time as function of the volume pipetted in the inlet well (n = 4–7). (C) 
Comparison of the deflection of the thin porous membrane during medium exchange between experimental 
data and the mathematical model data (n = 11).
Figure 3. Cell culture validation on the breathing chip. Experimental handling of the new lung-on-chip array 
was tested with a commercially available viability test and the 16HBE14o- cell line. Breathing mode (dynamic) 
was started on day 3. 16HBE14o- cells demonstrate under stretch a slightly increased viability (n = 3).
www.nature.com/scientificreports/
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In this study, we achieved successful cultivation of hAEpCs on a chip. Upon seeding, we observed good attach-
ment of freshly isolated ATII cells (day 0)40,65. After 2 days on the chip, the cell monolayer reached confluence, and 
on day 5 the majority of cells possessed an ATI-like phenotype with high expression of ATI cell marker caveolin-1 
and the tight junction protein Zo-1 (Fig. 4A, red staining). In addition, a small fraction of ATII-like cells was 
detected by immunofluorescence staining against mature SP-C (Fig. 4A, green label) or the ATP-binding cassette 
transporter (ABCa3). Both proteins are selective markers for ATII cells and specifically localized in lamellar bod-
ies (LBs), which are storage vesicles for pulmonary surfactant57,66,67. Furthermore, gene expression analysis of cells 
on chips under static conditions revealed that expression of proSP-C decreased, whereas gene expression of the 
ATI-specific protein caveolin-165,68 increased, over time (Fig. 4B,C). These observations on the gene expression 
level were confirmed by counting the total number of cells on the well and analyzing the ratio of mature ABCa3 
positive stained cells on day 1 and day 5 (Fig. S7). Expression of the apical sodium transporter EnaCα, designat-
ing polarized cells with active water transport capacity (Fig. 4D), also increased. Similar results were reported in 
previous studies, suggesting that ATI cells in vivo play an important role in lung fluid homeostasis61,68. The fine 
equilibration of the alveolar lining fluid is decisive for lung function, and fluid maladjustment impedes gas trans-
port and induces alveolar collapse due to high surface tension.
Recent observations demonstrated that besides tissue stretch, the air compartment (and thus the associated 
surface tension) is the most important physiological stimulus for surfactant release37,38,69. Thus, the creation of a 
confluent epithelial monolayer at the air–liquid interface is a key prerequisite for tissue-specific cell differentiation 
on the chip. As shown in Fig. 4A, a confluent monolayer of hAEpCs formed at the air–liquid interface after 5 days. 
Micrograph sections (60–80 nm thick) revealed that most of the area was covered by flat, simply structured cells 
(see Fig. S8A) with large ultrathin cell protrusions (<2 µm, Fig. 5Aiii,Biii), as described previously by Weibel21 
and Fuchs et al.65. The surface of ATI cells contains characteristic caveolae-like structures65,70, which we identified 
by immunofluorescence staining for caveolin-1 (Figs S7A and S8B). We also identified a round, much smaller 
cell type dispersed within the monolayer. These round cells contained a number of relatively electron-dense 
multi-lamellar vesicles (Fig. 5Ai,Bi, arrow). These LB-like vesicles generally appeared empty, potentially due to a 
Figure 4. Cell differentiation on the chip. (A) After 5 days in culture, primary alveolar epithelial cells were 
stained against surfactant-protein (SP)-C, (marker of alveolar type (AT)-II cells, green) and Zonula occludens 
(Zo)-1 (marker for tight junctions, red). ATII-like cells specifically expressed SP-C (green). ATI-like cells were 
characterized with flat and enlarged cell bodies. Scale bar: 20 μm. (B–D) Gene expression analysis of primary 
human alveolar epithelial cells (hAEpC) on chip over 7 days indicated a decrease of ATII-cell marker (proSP-C), 
an increase of ATI-cell marker (caveolin-1) and the epithelial sodium transport channel (ENaCα). Gene 
expressions for all days on chip were compared to freshly isolated cells at D0 (n = 6, each time point).
www.nature.com/scientificreports/
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methodological artefact arising during sample fixation. However, occasionally we were able to reconstruct specific 
phospholipid lamellae structures, indicating a functional and intact mature LB (Fig. 5Aii arrow)71.
The apical cell surfaces of both cell types were densely covered with tiny (200–500 nm) microvilli protru-
sions and high magnification revealed strong tight junctions between neighboring cells (Fig. 5Aii,Bii; arrow). 
Morphology of hAEpCs on chips were comparable to those reported by previous in vivo and in vitro studies65,72. 
Fig. 5Bi–iii show hAEpCs exposed to 72 h of stretching, from day 2 to day 5. Electron microscopic analysis 
revealed no apparent differences in cell differentiation and morphology between static and dynamic conditions. 
However, we must take into account the fact that these sample sections were only minute extracts of the total 
surface area of the chip, and the analysis was performed in a descriptive manner, focusing on general monolayer 
integrity and cell morphology. Future studies are required to achieve quantitative evaluation of how stretching 
affects proliferation and trans-differentiation of freshly cultured hAEpCs on chips. Furthermore, to optimize 
the ratio between ATI and ATII cells, it would be useful to systematically examine the cell culture protocol and 
conditions, including growth factor supplement, air–liquid interface treatment and stretch protocol, with the 
aim to reaching proportions comparable to those recently described by Weibel21. To our knowledge, this is the 
first time that ATI- and ATII-like cells have been co-cultured and identified on-chip, resembling an almost in 
vivo–like alveolar epithelium. The two cell types could clearly be distinguished from each other using selective 
markers and electron microscopy. These microscopic observations were strengthened with results obtained from 
gene expression analysis.
Previously, we reported that mechanical strain increases the transport of small hydrophilic molecules (FITC 
0.4KDa) in the 16HBE14o- cell line30. However, to reconstitute alveolar transport, implementation of a pri-
mary cell model is crucial, because most available alveolar epithelial cell lines (e.g., A549, R3/1, MLE-12, etc.) 
lack the ability to form tight junctions, resulting in low epithelial resistance and insufficient barrier function73. 
Therefore, we assessed the effect of cyclic physiological strain on the permeability properties of primary alveolar 
epithelial cells (hAEpCs) (Fig. 6A). These experiments revealed that the permeabilities of a small hydrophilic 
tracer, FITC-sodium, and of a macromolecule mimetic, RITC-dextran, were significantly increased when cells 
were exposed to 72 h of stretching from day 2 to day 5. Flux of FITC–0.4 kDa was about 7-fold higher under 
dynamic conditions (4.5 ± 1.3*10−6 cm/s) than under static conditions (0.65 ± 1.1*10−6 cm/s). The transport rate 
of RITC–70 kDa was increased to a similar extent, from 0.24 ± 0.43*10−6 cm/s (static) to 1.6 ± 0.54*10−6 cm/s 
(dynamic mode). To rule out that increased permeability is based on cell detachment and reduced cell number we 
performed whole-chip imaging and counted the total number of cells on the chip. As shown in Fig. 6B, the total 
number of cells was similar under static (7655 ± 1204) and dynamic (7516 ± 1444) conditions. Furthermore, cell 
monolayers on stretched membranes exhibited tight junction expression similar to that of non-stretched mem-
branes (Fig. 6C). These data differ considerably from the results of our previous study: 16HBE14o- exhibited a 
much smaller (1.5-fold) increase in FITC–0.4 kDa permeability and no significant increase in RITC–70 kDa flux. 
Figure 5. Transmission electron micrograph of air-liquid interface exposed human alveolar epithelial cells 
(hAEpC) in in static conditions (A i-iii) and dynamic conditions (B i-ii). Major parts of the surface were 
covered with an ultra-thin film of ATI-like cell protrusions. ATII-like cells were filled with lamellar-body like 
vesicle (A ii, arrow). Microvilli structures (arrow A ii and B ii) and tight junctions (arrow A iii) indicate integrity 
of the cell layer.
www.nature.com/scientificreports/
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This important difference in stretch sensitivity might be explained by differences in stretching time (21 h vs. 72 h) 
or the cell culture protocols used (submerged vs. air–liquid conditions), or the fact that 16HBE14o- are bronchial 
epithelial cells. It is also possible that primary alveolar cells are much more susceptible to mechanosensitive stim-
ulation than cell lines53.
This is the first on-chip study evaluating the effect of enduring, cyclic physiological stretch (8%) on hAEpCs. 
Future studies should investigate the underlying signal mechanisms, which remain unclear. Notably in this regard, 
however, studies with primary rat alveolar cells demonstrated that 1 h of biaxial stretch of 37% increased the 
permeability capacity of small uncharged molecules and affected peripheral Zo-1 expression74–76. These in vitro 
results were verified in whole-lung experiments using FITC-Albumin (55 kDa) as a tracer. Interestingly, only 
30 min of 12% stretch was sufficient to show a trend in permeability increase and with 37% biaxial stretch the 
effect was significant76. The authors reported that even low stretch magnitudes, in the physiological range, 
could induce similar cell responses if the exposure times were prolonged. Furthermore, the study revealed that 
stretching induces actin cytoskeleton reorganization, probably mediated by intracellular Ca2+ increase. This 
leads to multiplication of large cellular membrane pores, thereby increasing the transport of larger molecules 
like albumin76. These results emphasize the importance of assessing permeability under physiological breathing 
conditions.
As a next step towards an advanced alveolus-on-chip for drug transport studies, we recreated the alveolar 
air–blood barrier by establishing a co-culture of primary epithelial and endothelial cells. Previous studies showed 
that co-culture of epithelial and endothelial cells improves barrier properties and mimics in vivo signaling path-
ways in a more realistic way72,77. We managed to co-culture primary human alveolar epithelial (hAEpCs) and 
primary human lung microvascular endothelial cells (VeraVecs) over a 22-day time course. After 22 days in cul-
ture, hAEpCs and VeraVecs still expressed tight junction protein Zo-1 (Fig. 7A,B). The integrated 3.5-µm porous 
PDMS membrane allowed recreation of the very thin air–blood barrier in vitro, shown in Fig. 7C. The total local 
thickness of our barrier was less than 10 μm; for comparison, commercially available cell inserts routinely used 
for drug transport studies have a membrane thickness of 10 μm78 without cells. The thinness of our barrier brings 
us close to the in vivo dimension of the air–blood barrier, described by Gehr et al., with an alveolar arithmetic 
mean thickness of 2.2 µm79.
TEER measurements further revealed that barrier integrity matured over time, reaching a plateau after 7 days 
in co-culture (Fig. 7D); the maximal TEER value of 545.5 ± 2.86 Ω cm2 was reached at day 14. Although TEER 
in co-culture on our chip was smaller than previously described for hAEpCs in inserts (1000–2000 Ω cm2)80, 
these values reflected a tight monolayer enabling active water and selective ion transport73,77. Differences between 
TEER values measured in inserts and in microfluidic systems have been reported earlier and are thought to be due 
to a geometrical origin rather than a biological one81. Furthermore, TEER experiments often exhibit significant 
discrepancies, due to different culture conditions or (most probably) donor-to-donor variability73,77. Successful 
implementation of a non-invasive TEER measurement using standard equipment would enable live cell moni-
toring of cell growth, differentiation and barrier integrity, eliminating the need to integrate electrodes directly 
inside the chip, as previously reported82–85. After 22 days, when the culture was aborted, the co-culture and the 
barrier functionality were still intact. The experiments could have therefore been performed for longer periods 
of time for defined drug discovery or toxicity assay, such as acute inhalation toxicity studies86. To the best of our 
knowledge, this is the first study in which a co-culture of primary human lung epithelial and endothelial cells 
was established on a lung-on-chip device in a manner that enabled elevated TEER values to be established, main-
tained, and measured over a long period of time6,80.
Figure 6. The effect of cyclic strain on the permeability of primary alveolar epithelial cells. (A) Apparent 
permeability for FITC and RITC for static and dynamic conditions. The relative transport of a small hydrophilic 
molecule FITC-sodium (4 kDa) and RITC-dextran (70 kDa) across the monolayer significantly increased 
upon a physiological cyclic strain. Cyclic stretch was applied for 72 hours and a control was kept under static 
conditions (n = 5–6). (B) Cell number of primary alveolar epithelial cells in dynamic and static conditions. 
The mean cell number was equal in dynamic and static conditions. We used a Fiji macro (Unsharp Mask, 
Threshold, make binary, watershed & analyse particles) to quantify the images obtained by scanning a whole 
chip (n = 4–6). The analysis revealed that the number of cells is not influenced by the physiological stretch. (C) 
Tight junction expression. The fluorescence images show the cell nuclei in blue and the tight junction protein 
Zo-1 in red. In both conditions, Zo-1 was well expressed, which confirmed a tight cell monolayer and that the 
physiological stretch of 8% linear did not negatively influence the cell monolayer integrity. The images were 
taken in the centre of the cell culture well, where the stretch effect is maximal. Scale bars: 20 μm.
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Conclusion
The breathing lung-on-chip array described here mimics several key aspects of the alveolar microenvironment, 
such as the breathing motion, the air-blood barrier and the air-liquid interface. It enables to culture and maintain 
primary human ATI and ATII-like epithelial cells from patients’ for several days. Long-term co-cultures including 
human alveolar epithelial cells and endothelial cells are also possible thanks to the integrated passive cell culture 
medium exchange. In addition, the simple handling of the device and its compatibility with several standard 
laboratory instruments are serious advantages in view to its adoption in research as well as in the pharmaceutical 
industry. This also enables to establish reproducible cell culture conditions and assay protocols on the chip. The 
present study demonstrates that this alveolus-on-chip array is a valuable tool to model the alveolar barrier. It has 
the potential to become an important tool in drug discovery and in personalized and precision medicine appli-
cations to optimize the therapy of each patient based on results obtained on-chip with the patients’ own cells.
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